The Inflation Reduction Act’s drug negotiation provision represents the federal government’s most direct intervention into pharmaceutical pricing since the creation of Medicare Part D in 2003, when Congress famously prohibited CMS from negotiating drug prices at all. The intellectual reversal is remarkable. The practical implications, however, are more complex than either the law’s architects or its opponents have fully acknowledged — particularly in how Medicare negotiated prices interact with the commercial rebate system that governs pricing for the majority of Americans with private insurance.
The Negotiation Mechanism
The mechanism works roughly as follows: CMS selects high-expenditure drugs without generic or biosimilar competition from the Medicare Part D formulary, negotiates a maximum fair price with the manufacturer through a structured process, and implements that price for Medicare beneficiaries. The first ten drugs selected for negotiation — including eliquis, jardiance, and xarelto — represent categories with substantial commercial utilization as well. The negotiated prices, which CMS has released, are materially below current net commercial prices for several agents. The question that the pharmaceutical industry and policy analysts have been debating since the law’s passage is whether those Medicare prices will eventually anchor commercial prices — either through reference pricing, through regulatory extension, or through the negotiating leverage that commercial payers will derive from the existence of a publicly known government price.
The commercial rebate system complicates this transmission mechanism in ways that are not fully understood. Commercial prices for the drugs subject to IRA negotiation are net prices — gross list prices minus PBM-negotiated rebates — and the relationship between the Medicare maximum fair price and the commercial net price varies by drug, by payer, and by the specific rebate arrangements in place. A drug for which CMS has negotiated a Medicare price twenty percent below commercial list may already be trading at a similar net price in the commercial market after rebates; in that case, the Medicare negotiated price reveals relatively little about commercial excess. A drug for which commercial net prices remain substantially above the Medicare negotiated price represents a different situation — one where the Medicare price becomes an anchor that commercial payers will reference in their own negotiations.
The Best Price Interaction
There is also a Medicaid best price dimension to the IRA negotiation that has not received adequate attention. The law includes provisions specifying that Medicare negotiated prices do not constitute best price for Medicaid rebate calculation purposes — a carve-out that manufacturers lobbied for and obtained to prevent the Medicare negotiated price from triggering a corresponding Medicaid rebate reset. Without this carve-out, a deeply negotiated Medicare price would have created a Medicaid obligation that could have substantially increased manufacturer rebate liability. The carve-out preserves the independence of the two pricing regimes, which is commercially rational but may limit the cross-program price discipline that a unified reference price could have provided.
Second-Order Commercial Effects
The most consequential second-order effect of the IRA’s negotiation mechanism may be behavioral rather than direct. Manufacturers of drugs that are candidates for future negotiation rounds face a changed investment and pricing environment in which launch prices and rebate strategies must now account for the possibility of government price-setting several years into the drug’s commercial life. The behavioral response — higher launch prices to maximize revenue before potential negotiation, or accelerated efforts to add indications that would extend exclusivity — is difficult to model but impossible to ignore. CBO’s projections of IRA drug savings did not fully account for behavioral responses of this kind, and the realized savings may diverge substantially from the projected figures in either direction.
The interaction between Medicare drug negotiation and the commercial rebate system will take years to fully manifest. The initial negotiated prices are being implemented and litigated simultaneously — several manufacturers filed suit challenging the constitutional basis of the negotiation program, and the litigation outcomes will shape whether and how the mechanism scales. In the interim, the most immediate practical effect may be in the information it produces: publicly disclosed Medicare negotiated prices give commercial payers a reference point that they did not previously have, and even where the Medicare price does not legally bind the commercial market, the existence of a known government price changes the rhetorical and negotiating context for commercial contract discussions in ways that are difficult to quantify but probably significant.
